First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Kim-Son H, Neal, Joel W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459550/
https://www.ncbi.nlm.nih.gov/pubmed/23055691
http://dx.doi.org/10.2147/BTT.S26558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459550/
https://www.ncbi.nlm.nih.gov/pubmed/23055691
http://dx.doi.org/10.2147/BTT.S26558

Ejemplares similares